Prediction: New Reason Lilly Stock Could Still Rise
Eli Lilly stock could advance in the second half of 2026 as Foundayo gains traction and the GLP-1 franchise shines, b...
Certain index funds offer superior tax efficiency due to turnover and structure; evaluate these factors when building your lineup.
25,966 articlesEli Lilly stock could advance in the second half of 2026 as Foundayo gains traction and the GLP-1 franchise shines, b...
Johnson Johnson walking away from a GLP-1 obesity obsession signals a shift to a diversified, potentially more resili...
In 2026, two very different healthcare players—Abbott Laboratories and Glaukos—offer contrasting paths to potential g...
Johnson & Johnson and Coca-Cola posted strong Q1 2026 results as markets rotate toward defensive plays. The big quest...
Verizon raises its dividend with a high yield, while Johnson & Johnson offers steadier growth and a long payout histo...
Two power players, two paths: Constellation Energy and Vistra offer differing mixes of stability and upside. This gui...
Peloton and Uber represent two digitally enabled businesses with very different paths. This guide breaks down the num...
J.B. Hunt edges ahead on margin strength in a soft freight market, while ZIM faces a sharp drop in rates and merger r...
Boeing, Honeywell, and 3M all fell in after-hours trading as Q4 results rolled out, signaling divergent paths. This p...
Tesla posts stronger margins amid a delivery dip, while Rivian turns profitable on software and a hopeful R2 ramp. An...
Alphabet and Meta delivered divergent Q4 results, underscoring different paths to durable profits. Cloud, AI, and cap...
Intel and AMD delivered contrasting Q4 results, highlighting divergent paths: Intel grappling with foundry losses ami...